Generon (Shanghai) Corporation Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Shanghai China (2004)

Organization Overview

First Clinical Trial
2012
NCT01648322
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Generon (Shanghai) Corporation Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 3)

Graft vs Host Disease (Phase 2)

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Neutropenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 11